Berberine shows no advantage over placebo for reducing liver and belly fat

A multicenter research effort in China conducted clinical trial testing of oral berberine for six months in diabetes-free adults with obesity and metabolic dysfunction-associated steatotic liver disease. Visceral adipose tissue area and liver fat content showed no significant differences between berberine and placebo.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup